Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway

Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway

Imatinib (IM), as first inhibitor of the oncogenic tyrosine kinase BCR-ABL, has been widely used to treat chronic myeloid leukemia (CML) for decades in clinic. However, resistance to IM usually occurs in CML patients. The bone marrow (BM), as the predominant microenvironment of CML, secretes an abun...

Full description

Bibliographic Details
Main Authors:	Xiaobo Zhang, Yicheng Liu, Lu Lu, Shaoliang Huang, Youxiang Ding, Yi Zhang, Qinglong Guo, Zhiyu Li, Li Zhao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-08-01
Series:	Frontiers in Pharmacology
Subjects:	microenvironment cell co-culture drug resistance hedgehog pathway BCR-ABL Oroxyloside A
Online Access:	http://journal.frontiersin.org/article/10.3389/fphar.2017.00526/full

Similar Items

Pharmacokinetics of baicalin and oroxyloside in plasma and different tissues of rats after transnasal aerosol inhalation and intravenous injection of Tanreqing
by: Teng-Fei Chen, et al.
Published: (2022-08-01)

Kill Two Birds with One Stone: A Multifunctional Dual‐Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome‐Positive Leukemia
by: Bohan Ma, et al.
Published: (2022-05-01)

Monitoração molecular da Leucemia Mielóide Crônica na era do imatinibe Molecular monitoring of Chronic Myeloid Leukemia in the imatinib era
by: Israel Bendit
Published: (2008-04-01)

Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
by: Valia Pavón Morán, et al.
Published: (2005-12-01)

Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study
by: Manar Mohamd Mohamad Ismail, et al.
Published: (2013-12-01)

A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells
by: Patricia Martín-Rodríguez, et al.
Published: (2019-01-01)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
by: Anna Kreutzman, et al.
Published: (2019-09-01)

Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
by: Mousa Vatanmakanian, et al.
Published: (2019-04-01)

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011-12-01)

Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia
by: Rachid Lahlil, et al.
Published: (2023-11-01)

Apoptosis resistance in chronic myelogenous leukemia
by: Fabíola Attié de Castro, et al.
Published: (2005-09-01)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
by: Liuya Wei, et al.
Published: (2020-09-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
by: Dachuan Zeng, et al.
Published: (2022-05-01)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
by: Matteo D’Addona, et al.
Published: (2022-06-01)

Mutations Associated with Imatinib Mesylate Resistance - Review
by: Linev Alexandar J., et al.
Published: (2018-12-01)

Nilotinib efficacy in a patient resistant to imatinib
by: Luigia Luciano
Published: (2015-10-01)

Transcripto BCR-ABL atípico en un paciente con leucemia mieloide crónica Atypical BCR-ABL transcript in a patient with chronic myeloid leukemia
by: Ana María Amor Vigil, et al.
Published: (2011-09-01)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
by: Abhilash Chandra, et al.
Published: (2020-04-01)

Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib
by: Giuseppe Pietrantuono
Published: (2015-10-01)

Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells
by: Shi D, et al.
Published: (2016-11-01)

Influence of late treatment on how chronic myeloid leukemia responds to imatinib
by: Ana Carolina Costa Scerni, et al.
Published: (2009-01-01)

Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety
by: Mehlika Dilek Altıntop, et al.
Published: (2017-12-01)

Nilotinib early switch efficacy in non-optimal responder CML patient after first line imatinib treatment
by: Ferdinando Porretto
Published: (2015-10-01)

Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012-01-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

A study to determine the clinical, hematological, cytogenetic, and molecular profile in CML patient in and around Eastern UP, India
by: Sandip Kumar, et al.
Published: (2019-01-01)

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
by: Flis S, et al.
Published: (2019-03-01)

Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital
by: Samuel Roosevelt Campos dos Reis, et al.
Published: (2013-06-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML
by: Zilin Li, et al.
Published: (2024-04-01)

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
by: Ol'ga Yur'evna Vinogradova, et al.
Published: (2009-07-01)

Effect of Plumbagin on growth inhibition and apoptosis of imatinib-resistant chronic myeloid leukemia
by: Bui Thi Kim Ly, et al.
Published: (2017-08-01)

Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients
by: Negar Nouri, et al.
Published: (2023-01-01)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
by: Xiaoying Lan, et al.
Published: (2016-11-01)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
by: Hao Zhang, et al.
Published: (2022-03-01)

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
by: Khateb Mamduh, et al.
Published: (2012-11-01)

Preleukemic phase of chronic myelogenous leukemia: A diagnostic dilemma highlighting the significance of integrated reporting
by: Neelum Mansoor, et al.
Published: (2023-03-01)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
by: Melissa Pereira Machado, et al.
Published: (2011-06-01)